Upadacitinib for Non-Segmented Vitiligo Study
Researchers at Stanford University are conducting a study in adolescents ages 12-17 to evaluate an investigational oral medication for non-segmented vitiligo.
Fast Facts
Diagnosed with Non-Segmental Vitiligo
12-17 Years Old
Investigational Oral Medication
Conducted in Redwood City, CA
Study Background
Researchers at Stanford University are partnering with AbbVie to conduct a study in adolescents ages 12-17 and older to evaluate an investigational oral medication for non-segmented vitiligo.
Vitiligo is a common chronic autoimmune disorder of the skin which presents as patches of pigment loss. Currently, there are no known cures or preventive options for vitiligo, and few treatment options exist. In this research study, we want to test the safety and effectiveness of an investigational drug called upadacitinib.
If you are 12-17 years old and have non-segmental vitiligo, you may be eligible to participate. Eventually, we hope the findings of this study might be useful for treating vitiligo and improving people’s quality of life.
Study Background
Researchers at Stanford University are conducting a study in adolescents and adults ages 12 and older to evaluate an investigational medication for non-segmented vitiligo.
Vitiligo is a common chronic autoimmune disorder of the skin which presents as patches of pigment loss. Currently, there are no known cures or preventive options for vitiligo, and few treatment options exist. In this research study, we want to test the safety and effectiveness of an investigational drug called upadacitinib.
If you are 12 years or older and have non-segmental vitiligo, you may be eligible to participate. Eventually, we hope the findings of this study might be useful for treating vitiligo and improving people’s quality of life.
Additional Information
In this research study, we want to evaluate the safety and effectiveness of upadacitinib, an investigational drug for non-segmental vitiligo. We theorize that this drug will interfere with signals in the body that cause inflammation and prevent the destruction of pigmentation cells (melanocytes).
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- 12-17 years old
- Diagnosed with non-segmental vitiligo
Exclusion Criteria:
- Other active skin diseases
- Heavy drug/alcohol use
- Pregnancy
- HIV or HPV
- Recent heart attack
- Thyroid disease
- History of being treated with permanent skin bleaching agents
- Have been treated with investigational drug in last 30 days
This study involves 20 in-person clinic visits. Full participation includes:
- Screening Period (35 days)
- Treatment period with investigational upadacitinib (48 weeks). Some participants will be randomly assigned to receive the study drug, and some will be assigned to receive a placebo, which look like the study drug but contains no active medication. Neither you nor the researchers will know which one you are getting.
- Open-label extension period, meaning you will know what medication you are receiving (112 weeks)
- Follow-up period (30 days)
There is no cost for you to participate in our research study.
